The metabolic syndrome, type 2 diabetes, and cardiovascular disease: Understanding the role of insulin resistance

American Journal of Managed Care

Volumn 8, Issue 20 SUPPL., 2002, Pages

  Kendall, D M ^a   Harmel, A P ^a  

^a INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC RESTRICTION; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; CLINICAL PROTOCOL; CORONARY ARTERY BYPASS GRAFT; DIABETES CONTROL; DIABETIC HYPERTENSION; DIABETIC OBESITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; ENDOTHELIUM INJURY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENICITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; STROKE; THORAX PAIN; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; WEIGHT REDUCTION;

EID: 0036918943     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetes Med. 1998;15:539-553.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
3. American Association for Clinical Endocrinology Web site. http://www.aace.com/members/socio/syndromex.php. Accessed September 24, 2002.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1600.
6. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes. 1992;41:715-722.
7. Reave GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
8. Kylin E. Studien uber das Hypertonie-Hyperglykamie-Hyperurikamiesyndrome. Zentralblatt fur Innere Medizin. 1923;44:105-127.
9. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
10. Yip P, Facchini FS, Reaven GM. Resistance to insulin mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab. 1998;83:2773-2776.
11. Reaven G. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286-288.
12. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713-718.
13. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
14. Sobel BE. Insulin resistance and thrombosis: A cardiologist's view. Am J Cardiol. 1999;84:37J-41J.
15. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 1998;47:290-293.
16. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol. 1999;84:21J-24J.
17. Festa A, D'Agostino RJ, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
18. AACE Task Force on IRS. Consensus Conference. August 2000; Washington, DC.
19. American Diabetes Association. 2002 clinical practice recommendations. Diabetes Care. 2002;25(suppl 1):S1-S47.
20. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
21. The DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;21:617-621.
22. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-692.
23. Kendall DM, Bergenstal RM. Comprehensive management of type 2 diabetes: Establishing priorities of care. Am J Manag Care. 2001;7(suppl 10):S327-S343.
24. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
25. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care. 2002;25:1845-1850.
26. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
27. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20:935-942.
28. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-953.
29. Stratton IM, Adler AI, Neil HAW, et al, for the United Kingdom Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
30. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
31. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
32. Knowler WC, Barrett-Connor E, Fowler SE, et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
33. Reaven GM. Diet and syndrome X. Curr Atheroscler Rep. 2002;2:503-507.
34. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000;133:92-103.
35. Rickheim PR, Weaver TW, Flader J, Kendall DM. Effectiveness of group vs individual diabetes education: A randomized clinical trial. Diabetes Care. 2002;25:269-274.
36. Perseghin G, Price TB, Petersen KF. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med. 1996;18:1357-1362.
37. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;2:61-72.
38. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512-1515.
39. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
40. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
41. Steiner G. Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88(12a):37N-40N.
42. Gordon T, Castelli WP, Hjortland MC, et al. High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
43. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
44. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
45. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: Subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care. 1997;20:614-620.
46. The Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513-2519.
47. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
48. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
49. Grundy S, Vega G, McGovern M, et al, for the Diabetes Multi-Center Research Group. Efficacy, safety and tolerability of extended-release niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568-1576.
50. Nass CM, Blumenthal RS. The effect of glitazones on lipid profiles. Am J Manag Care. 2000;6:S1247-S1256.
51. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice. Endocr Pract. 2001;7:162-169.
52. Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708-711.
53. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Sixth report. Arch Intern Med. 1997;157:2413-2446.
54. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
55. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:733-720.
56. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
57. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
58. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension (ABCD). N Engl J Med. 1998;338:645-652.
59. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
60. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
61. Brenner BM, Cooper ME, De Zeeuw D, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
62. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661-2667.
63. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999;48:1448-1453.
64. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest. 1995;96:354-360.
65. Kaufman LN, Peterson MM, DeGrange LM. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism. 1995;44:1105-1109.
66. Colwell JA. Aspirin therapy in diabetes. (Technical Review). Diabetes Care. 1997;20:1767-1771.
67. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268:1292-1300.
68. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.